179173-99-0

Basic information

• Product Name: cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine
• Synonyms: cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine
• CAS NO: 179173-99-0
• Molecular Weight: 451.571
• Mol File: 179173-99-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine(179173-99-0)
• EPA Substance Registry System: cis-1-[[1-[3-(4-Aminophenyl)-3-phenylpropenoyl]-4-piperidyl]methyl]-1H-2-methylimidazo[4,5-c]pyridine(179173-99-0)

Safety Data

• Hazardous Substances Data: 179173-99-0(Hazardous Substances Data)

Upstream product

• 21320-81-0 ethyl 3-(4-nitrophenyl)-3-phenylacrylate 
• 1144-74-7 4-nitrobenzophenone 
• 173604-54-1 1-[(4-piperidyl)methyl]-1H-2-methylimidazo[4,5-c]pyridine 
• 188913-63-5 1-[4-(2-methyl-imidazo[4,5-c]pyridin-1-ylmethyl)-piperidin-1-yl]-3-(4-nitro-phenyl)-3-phenyl-propenone 
• 17683-99-7 E/Z-3-(4-nitrophenyl)-3-phenylpropenoic acid 

Downstream Products

• 188913-58-8 (E)-2-hydroxy-5-[[4-[3-[4-[(2-methyl-1H-imidazo[4,5-c]pyridin-1-yl)methyl]-1-piperidinyl]-3-oxo-1-phenyl-1-propenyl]phenyl]azo]benzoic acid 

Relevant articles and documents

Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity

This paper describes the synthesis of a series of azo compounds able to deliver 5-aminosalicylic acid (5-ASA) and a potent platelet activating factor (PAF) antagonist in a colon-specific manner for the purpose of treating ulcerative colitis. We found it p

Piperidine derivatives with PAF antagonist activity

Compounds of general formula I and their salts and solvates are PAF antagonists and as such are useful in the treatment of various diseases or disorders mediated by PAF. Pharmaceutical compositions including these compounds and processes for their prepara